高频经颅随机噪声刺激作为精神分裂症持续症状附加治疗的研究方案:多中心、双盲、随机假对照临床试验
该研究为多中心、双盲、随机假对照试验,计划纳入144例精神分裂症持续症状患者,随机分配接受活性或假高频经颅随机噪声刺激(hf-tRNS),主要结局为10次治疗后的应答者数量。研究假设活性hf-tRNS对症状严重程度有持久效应,并探讨其生物学与认知效应及临床应答预测因素。
要点
- 144例精神分裂症持续症状患者随机接受活性或假hf-tRNS,每组72例。
- 活性hf-tRNS参数为100-500 Hz、2 mA(1 mA偏移)、每日两次、连续5个工作日,共10次。
- 主要结局为10次治疗后PANSS评分较基线降低至少25%的应答者数量。
核心结论
- 该试验结果将构成确立hf-tRNS在精神分裂症中 usefulness 的第一步,无论疾病阶段和治疗抵抗水平如何。
- 作者假设活性hf-tRNS对精神分裂症症状严重程度的效应较假刺激持久。
- 该试验还将对hf-tRNS作为精神分裂症患者复发预防干预措施的应用产生影响。
研究设计与样本
- 多中心、双盲、2臂平行组、随机假对照临床试验。
- 计划纳入144例精神分裂症患者,尽管已处方至少一种抗精神病药治疗但仍存在持续症状。
- 患者随机分配接受活性hf-tRNS(n=72)或假hf-tRNS(n=72)。
主要发现
- hf-tRNS(100-500 Hz)以2 mA电流强度和1 mA偏移每日两次、连续5个工作日、每次20分钟递送。
- 阳极置于左侧背外侧前额叶皮层,阴极置于左侧颞顶交界处。
- 主要结局为10次治疗后PANSS评分较基线降低至少25%的应答者数量。
- 次要结局包括脑活动与连接、来源监测表现、社会认知、其他临床(包括听幻觉)和生物学变量,以及治疗态度。
关键数值与推荐
- 应答者定义为10次hf-tRNS治疗后PANSS评分较基线降低至少25%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One out of three patients with schizophrenia failed to respond adequately to antipsychotics and continue to experience debilitating symptoms such as auditory hallucinations and negative symptoms. The development of additional therapeutic approaches for these persistent symptoms constitutes a major goal for patients. Here, we develop a randomized-controlled trial testing the efficacy of high-frequency transcranial random noise stimulation (hf-tRNS) for the treatment of resistant/persistent symptoms of schizophrenia in patients with various profiles of symptoms, cognitive deficits and illness duration. We also aim to investigate the biological and cognitive effects of hf-tRNS and to identify the predictors of clinical response. METHODS: In a randomized, double-blind, 2-arm parallel-group, controlled, multicentre study, 144 patients with schizophrenia and persistent symptoms despite the prescription of at least one antipsychotic treatment will be randomly allocated to receive either active (n = 72) or sham (n = 72) hf-tRNS. hf-tRNS (100-500 Hz) will be delivered for 20 min with a current intensity of 2 mA and a 1-mA offset twice a day on 5 consecutive weekdays. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode over the left temporoparietal junction. Patients' symptoms will be assessed prior to hf-tRNS (baseline), after the 10 sessions, and at 1-, 3- and 6-month follow-up. The primary outcome will be the number of responders defined as a reduction of at least 25% from the baseline scores on the Positive and Negative Syndrome Scale (PANSS) after the 10 sessions. Secondary outcomes will include brain activity and connectivity, source monitoring performances, social cognition, other clinical (including auditory hallucinations) and biological variables, and attitude toward treatment. DISCUSSION: The results of this trial will constitute a first step toward establishing the usefulness of hf-tRNS in schizophrenia whatever the stage of the illness and the level of treatment resistance. We hypothesize a long-lasting effect of active hf-tRNS on the severity of schizophrenia symptoms as compared to sham. This trial will also have implications for the use of hf-tRNS as a preventive intervention of relapse in patients with schizophrenia. TRIAL REGISTRATION: ClinicalTrials.gov NCT02744989. Prospectively registered on 20 April 2016.
引用
- Brunelin J, Mondino M, Haesebaert J, et al. Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIM'Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial. Trials. 2021. PMID: 34963486. doi:10.1186/s13063-021-05928-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。